Cognition Therapeutics, Inc. (CGTX): history, ownership, mission, how it works & makes money

A Brief History of Cognition Therapeutics, Inc. (CGTX)

Founding and Initial Development

Cognition Therapeutics, Inc. (CGTX) was founded in 2013, focusing on developing therapies for neurodegenerative diseases. The company is headquartered in Pittsburgh, Pennsylvania. It aims to address the urgent need for effective treatments targeting Alzheimer’s disease and related cognitive disorders.

Research Focus and Innovations

The core technology behind CGTX involves the identification of synaptic degeneration in Alzheimer's disease. The lead compound from their research, CT1812, is designed to modulate the sigma-2 receptor, which is implicated in synaptic health and cognitive function.

Funding and Financial Milestones

As of October 2023, Cognition Therapeutics has raised approximately $66.4 million in total funding across multiple rounds. Significant financial milestones include:

• Series A Funding (2013): $5 million
• Series B Funding (2019): $15 million
• Initial Public Offering (2021): Raised $25 million
• Subsequent Funding Rounds: $21.4 million

Clinical Trials and Progress

CGTX has been actively involved in clinical trials for CT1812. Key milestones in the clinical development include:

• Phase 1 Trials Initiated: 2020
• Phase 2 Trials Completed: January 2022
• Phase 2b Trials Initiated: September 2022

The company reported positive safety and tolerability results from the Phase 2 trials, leading to further studies with a larger patient cohort.

Market Impact and Stock Performance

Cognition Therapeutics went public via an initial public offering (IPO) on the Nasdaq under the ticker symbol CGTX on April 7, 2021. The IPO priced shares at $5.00, raising significant capital for further development. By October 2023, CGTX shares were trading at approximately $7.20, reflecting a market capitalization of around $85 million.

Collaborations and Partnerships

CGTX has entered into various collaborations to enhance its research and development capabilities. Notable partnerships include:

• Collaboration with the University of Pittsburgh: Focus on neurodegenerative research
• Partnership with Alzheimer’s Disease Cooperative Study: Co-developing clinical trials

Recent Developments and Future Outlook

As of the end of Q3 2023, Cognition Therapeutics is gearing up for upcoming clinical trial results and potential regulatory submissions. The company aims to present findings at the upcoming Alzheimer’s Association International Conference (AAIC) in 2024.

A Who Owns Cognition Therapeutics, Inc. (CGTX)

Ownership Structure

Cognition Therapeutics, Inc. (CGTX) has a diverse ownership structure that includes institutional investors, retail investors, and company insiders. As of the latest filings, the ownership distribution is as follows:

Major Shareholders

The largest shareholders of Cognition Therapeutics, Inc. include both institutional investors and notable individuals. The following table provides an overview of the major shareholders:

Market Capitalization

As of the latest trading day, Cognition Therapeutics, Inc. has a market capitalization of approximately $65 million. The trading volume has been reported at an average of 150,000 shares per day.

Recent Stock Performance

The stock price of CGTX has experienced fluctuations over the past year. Below is a summary of the stock performance:

Insider Transactions

Recent insider transactions indicate active participation by company executives. Below are some notable transactions:

Future Ownership Projections

Analysts have estimated the potential changes in ownership structure over the next few years. These projections are based on anticipated market movements and company performance:

Cognition Therapeutics, Inc. (CGTX) Mission Statement

Company Overview

Cognition Therapeutics, Inc. (CGTX) is a biopharmaceutical company focusing on developing innovative therapies for Alzheimer’s disease and other neurodegenerative diseases. The company aims to restore cognition and address underlying disease mechanisms.

Mission Statement

The mission of Cognition Therapeutics, Inc. is to transform the treatment landscape for Alzheimer’s disease through groundbreaking research and the development of novel therapeutics targeting the underlying biological pathologies associated with the disease.

Research and Development Focus

CGTX is dedicated to the following areas:

• Targeting amyloid precursor protein (APP) and its metabolites.
• Investigating neuroinflammation as a therapeutic target.
• Advancing small molecule drug candidates.

Financial Data

As of Q3 2023, Cognition Therapeutics reported the following financial statistics:

Commitment to Patients

Cognition Therapeutics emphasizes its commitment to patients and caregivers by:

• Prioritizing patient-centric clinical trials.
• Engaging in transparent communication with stakeholders.
• Building partnerships with research institutions and advocacy groups.

Market Position

As of early 2023, the Alzheimer’s disease market was valued at approximately USD 10.7 billion and is expected to grow to USD 20.1 billion by 2030. CGTX is strategically positioned to capture market share with its innovative therapies.

Pipeline and Products

The company’s major product candidates include:

• CT1812 – a small molecule in Phase 2 clinical trials.
• CT227 – an investigational drug targeting neuroinflammation.

Strategic Partnerships

CGTX has established collaborations with various academic and industry partners to facilitate its research and development efforts:

• Partnership with the University of California, San Diego for drug development.
• Collaboration with Alzheimer's Association for awareness and clinical research.

Future Prospects

Looking forward, Cognition Therapeutics aims to:

• Expand its clinical trial programs.
• Enhance its intellectual property portfolio.
• Advance towards commercialization of its therapeutic candidates.

How Cognition Therapeutics, Inc. (CGTX) Works

Business Overview

Cognition Therapeutics, Inc. (CGTX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for Alzheimer's disease and other neurodegenerative disorders. The company aims to address cognitive decline by targeting disease-modifying mechanisms.

Research and Development

CGTX's lead product candidate, CT1812, targets the sigma-2 receptor, which is implicated in neurodegeneration. As of October 2023, the company has completed Phase 1 and Phase 2 clinical trials.

Financial Statistics

As of Q3 2023, Cognition Therapeutics reported the following financial metrics:

Clinical Trials

CGTX has initiated several clinical trials for its lead compound CT1812:

• Phase 1 Trial: Completed in 2022, demonstrated safety and tolerability.
• Phase 2 Trial: Ongoing, with preliminary results projected for Q4 2023.

Partnerships and Collaborations

Cognition Therapeutics engages in strategic partnerships to enhance its research capabilities. Recent collaborations include:

• Partnership with the Alzheimer's Drug Discovery Foundation (ADDF) in 2023.
• Collaboration with academic institutions for translational research.

Market Conditions and Position

The global Alzheimer's disease market was valued at approximately $9 billion in 2022. The market is projected to grow at a CAGR of 10.6% from 2023 to 2030, reaching an estimated $22 billion by 2030.

Stock Performance

As of October 2023, the stock performance of Cognition Therapeutics (CGTX) is as follows:

Intellectual Property

Cognition Therapeutics holds several patents related to its novel compounds and therapeutic approaches, securing a competitive edge in the industry.

Future Outlook

CGTX is anticipating significant milestones in the upcoming quarters:

• Final results from the Phase 2 clinical trial by the end of 2023.
• Potential initiation of Phase 3 trials in 2024 depending on trial outcomes.

How Cognition Therapeutics, Inc. (CGTX) Makes Money

Revenue Streams

Cognition Therapeutics, Inc. generates revenue primarily through the following streams:

• Grants
• Collaborative Research Agreements
• Product Development Partnerships

Grants and Funding

The company has received substantial funding from various governmental and private organizations. As of 2023, Cognition Therapeutics secured a grant of $3 million from the National Institute on Aging (NIA) to support its research activities.

Collaborative Research Agreements

Cognition Therapeutics engages in collaborative research agreements with other pharmaceutical companies and academic institutions. These agreements may include upfront payments, milestone payments, and royalties on future sales. In 2022, Cognition entered a partnership with a major pharmaceutical firm, resulting in an initial payment of $5 million.

Product Development Partnerships

In addition to collaboration, the company pursues product development partnerships that allow it to share the costs and risks associated with drug development while retaining certain rights over the eventual products.

Clinical Trials Funding

Clinical trials are a critical part of Cognition's revenue generation. These trials often come with funding from external sources. For instance, Cognition announced in its latest quarterly report that it received $1.2 million in funding to support its Phase 2 clinical trial for its lead drug candidate, CT1812.

Financial Performance

According to the most recent financial report, Cognition Therapeutics reported:

Market Strategy

Cognition Therapeutics focuses on neurology and Alzheimer's drug development, targeting a market that is projected to reach $30 billion by 2026. The company aims to position itself strategically in this growing market through innovative approaches.

Intellectual Property Assets

The company holds a robust portfolio of patents that provide exclusive rights to its drug candidates. As of 2023, Cognition Therapeutics has filed for 15 patents related to its compounds and methods of treating cognitive disorders.

Future Projections

Analysts predict that if Cognition successfully advances its drug candidates through clinical trials, the potential revenue from licensing agreements could exceed $100 million by 2025. The company is also exploring opportunities for partnership in Europe and Asia to expand its market reach.